PPARγ Agonist-Loaded PLGA-PEG Nanocarriers as a Potential Treatment for Alzheimer’s Disease: In vitro and in vivo Studies [Corrigendum]

This article refers to:

PPARγ agonist-loaded PLGA-PEG nanocarriers as a potential treatment for Alzheimer’s disease: in vitro and in vivo studies

Silva-Abreu M, Calpena AC, Andrés-Benito P, et al. Int J Nanomedicine. 2018;13:5577–5590.

In the published article, there was an error in Figure 6A on page 5585. The image for Rhod-NPs was duplicated by a mislabeling of the image files. A new image for Rhod-NPs has been updated (bottom right). The authors apologize for this error and state that this does not change the quality and scientific conclusions of the article in any way.

The correct Figure 6 is as follows.

Figure 6 (A) Images of PGZ-NPs and Rhod-NPs by TEM after 6 hours in the basolateral compartment. (B) Permeability of hCMEC/D3, following exposure to 1 μg/mLof NPs for 6 hours. TNFα+ IFNγ (10 ng/mL, for 24 hours) was used as a positive control, increasing endothelial permeability.

Notes: Each value is the mean of three independent experiments. ns=nonsignificant, *P<0.05 by one-way ANOVA and Dunnett’s multiple comparison test (n=3).

Abbreviations: PGZ-NPs, PGZ-loaded nanoparticles; Rhod-NPs, Rhod-nanoparticles; hCMEC/D3, human brain endothelial cell line; TEM, transmission electron microscopy; TNF_α, tumor necrosis factor_α; IFN_γ, interferon; Pe, permeability coefficient.

In addition, an error by the journal during the preparation of Figure 7 led to the inadvertent creation of duplicate regions in Figure 7C on page 5586. The journal wishes to apologize for this error.

The correct Figure 7 is as follows.

Figure 7 In vivo evaluation of PGZ-NPs.

Notes: (A) Memory performance of treated animals in the two-object recognition test. APP/PS1 animals treated with vehicle showed cognitive impairment when compared with wild-type littermates. In contrast, Free-PGZ and PGZ-NPs treatment reduced the memory impairment in APP/PS1 mice. (B) Cortical Aβ burden is not significantly modified in treated APP/PS1 mice, in spite of the tendency to decreased deposition in NP-PGZ-treated animals. (C) Representative images of Aβ immunoreactivity in cortical sections of APP/PS1 mice chronically treated with Free-PGZ, PGZ-NPs or vehicle. Scale bar=200 μm. Data are expressed as the mean ± SEM. **P<0.01 compared to WT animals. ^$P<0.05, ^$$P<0.01 compared to vehicle group.

Abbreviations: PGZ-NPs, PGZ-loaded nanoparticles; PGZ, pioglitazone; WT, wild-type; VEH, vehicle.